Carcereny E, Felip E, Reck M, et al. Updated Efficacy Results From the BIRCH Study: First-Line Atezolizumab Therapy in PD-L1–Selected Patients With Advanced NSCLC. 18th World Conference on Lung Cancer (WCLC) 2017, abstract OA 17.02.
Ceritinib versus chemotherapie bij gevorderd ALK-positief NSCLC: ASCEND-4
mrt 2017 | Longoncologie